Poxel S.A.
OTC: PXXLF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nicolas Trouche
- Employees
- 6
- Headquarters
- Lyon, France
- IPO year
- 2017
- Market cap
- $15.9M
- Website
- https://www.poxelpharma.com
Loading PXXLF…
Loading profile data…Frequently asked questions about PXXLF
What does Poxel S.A. (PXXLF) do?
Poxel S.A., a biopharmaceutical firm in the clinical stage, is dedicated to creating innovative treatments for a range of metabolic disorders, including type 2 diabetes and various liver ailments. Its flagship product, Imeglimin, is an oral drug candidate that has successfully completed Phase III clinical trials in Japan. This promising medicati...
Where does PXXLF trade?
Poxel S.A. (PXXLF) trades on the Other OTC.
What sector is PXXLF in?
Poxel S.A. (PXXLF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Poxel S.A.?
Nicolas Trouche is the chief executive officer of Poxel S.A. (PXXLF).
Where is Poxel S.A. headquartered?
Poxel S.A. is headquartered in France.
Does PXXLF pay a dividend?
Poxel S.A. (PXXLF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PXXLF go public?
Poxel S.A. (PXXLF) completed its initial public offering in 2017.